Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- LDP Closes Discussions on Fee Cuts to Be Imposed on Hospitals, Pharmacies with Low Price Settlement Rates
February 25, 2014
- MHLW to Set Up Complaint Hotline for Hospitals, Pharmacies Upon Introduction of Penalty for Low Price Settlement Rates
February 25, 2014
- Astellas Unit, 12 Others Prequalified for Expedited Product Importation under FDA Pilot Program
February 21, 2014
- PFSB Issues Director Notification Calling for Revision of Package Inserts for Products Including Kiklin, Stivarga
February 20, 2014
- Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
- MHLW to Form Panel to Combat Counterfeit Drugs
February 19, 2014
- Deputy Director Masuyama of ELD Stresses Need to Establish Separate Guidelines for Different Biosimilars at SRSM Symposium
February 19, 2014
- PAFSC Second Committee to Discuss H5N1 Vaccines on Feb. 28
February 18, 2014
- “Politicians Should Not Intervene” in Dispute Over Rule to Reduce Medical Fees Claimed: Parliamentary Secretary of Health
February 18, 2014
- 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
- Diet Begins Discussions on 2 Bills Related to Establishment of “Japanese NIH,” Aimed at Commercialization of Innovative New Drugs
February 17, 2014
- Joint Purchasing May Rise as Hospitals with Low Settlement Rates Face Cuts in Fees Claimed: Chuikyo Member
February 17, 2014
- Kaketsuken Makes Another Bid to Fill Unmet Flu Vaccine Quota for 25 Million People
February 14, 2014
- FY2014 Medical Fee Revision to Limit Premium for Atypical Antipsychotics to Prescriptions with 2 or Fewer Drugs
February 14, 2014
- FY2014 NHI Drug Pricing Reform – Part 4: “Precursor Premium” to Be Introduced, but Hurdle Will Be High; Prices of a Wider Range of New Products to Be Adjusted Based on Average Foreign Prices
February 14, 2014
- FY2014 NHI Drug Pricing Reform – Part 3: Full Introduction of Premium for New Drug Development Rejected Again
February 14, 2014
- PAFSC’s 1st Committee to Review Prasugrel, 3 Combination Antihypertensives on Feb. 24
February 13, 2014
- Upper Limit for Evaluating Rate of Generic Drug Use of DPC Hospitals to Be 60%: Chuikyo’s Recommendation for FY2014 Reform
February 13, 2014
- Prescription, Medication Fees Received for 30-Day or Longer Prescriptions to Be Reduced by 40% at Large Hospitals: FY2014 Medical Fee Reform
February 13, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…